stock-detail (NVS)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Broccoli Sprout Extract May Protect Against Oral Cancer Recurrence

6/23/2016 10:05 am

(UPMC) June 23, 2016 - Potent doses of broccoli sprout extract activate a “detoxification” gene and may help prevent cancer recurrence in survivors of head and neck cancer, according to a trial by the University of Pittsburgh Cancer Institute, partner with UPMC Cancer Center, confirming preliminary results presented last year at the American Association for Cancer Research Annual Meeting.

Study Finds Surgery Can Lengthen Survival Of Metastatic Kidney Cancer Patients

6/21/2016 12:01 pm

(Dana-Farber) June 20, 2016 - Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Study Finds Patient Navigators Improve Comprehensive Cancer Screening Rates

6/21/2016 12:01 pm

(Mass General) June 20, 2016 - A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators – individuals who assist patients in receiving health care services – may improve comprehensive cancer screening rates among patient populations not likely to receive recommended screenings.

Novartis Aims To Nearly Triple Biosimilar Drugs On Market By 2020

6/20/2016 12:02 pm

(Reuters) June 20, 2016 - Switzerland's Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals' profits.

Snapshot of a Case-Based Financial Advocacy Network Workshop

6/15/2016 12:00 pm

(ACCCBuzz) June 15, 2016 - ACCC recently held its first Financial Advocacy Network (FAN) Case-Based Workshop of 2016.

Presurgery Chemotherapy May Make Advanced Ovarian Cancers Responsive to Immunotherapy

6/15/2016 11:05 am

(AACR) June 15, 2016 - Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Will CAR-T Deliver On The Promise Of Widespread Therapeutic Improvement?

6/9/2016 11:02 am

(MedCity News) June 8, 2016 - So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?

J&J Myeloma Drug, In Combo Regimen, Delays Worsening Of The Disease

6/5/2016 05:05 pm

(Reuters) June 5, 2016 - Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.

New Immune Therapy Drug Gives Bladder Cancer Patients Fresh Hope

6/5/2016 05:05 pm

(NBC News) June 5, 2016 - A newly approved drug that gives the immune system a boost helped stall the spread of tumors in patients with advanced bladder cancer, researchers reported Sunday.

U.S. FDA Staff Posts Voting Questions For Teva's Opioid Painkiller

6/4/2016 06:00 pm

(Reuters) June 3, 2016 - U.S. Food and Drug Administration staff released voting questions on Teva Pharmaceutical Industries Ltd's long-acting opioid painkiller for a panel of independent experts who will recommend to the agency whether to approve the drug.

Novartis Data Show More Than 50 Percent Of Eligible Ph+ CML Patients Maintain Treatment-free Remission (TFR) After Stopping Tasigna®

6/4/2016 05:03 pm

(Benzinga) June 4, 2016 - Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program.

New JTCC Studies Demonstrate Clinical And Economic Value Of Genomic Profiling In Improving Care And Outcomes In Non-Small Cell Lung Cancer And Breast Cancer

6/4/2016 05:01 pm

(The Business Journals) June 4, 2016 - Two new studies co-authored by researchers from John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and discussed at the American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potentially substantial therapeutic benefit of genomic profiling in serious, life-threatening cancers.

Vermont Poised To Become First State To Require Pharma To Justify Pricing

5/23/2016 12:01 pm

(STAT/Pharmalot) May 19, 2016 - In less than a month, Vermont could become the first state in the country to require drug makers to justify price hikes on their medicines, a move that may prompt others to take similar action but also spark a battle with the pharmaceutical industry.

Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE(R) (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer

5/19/2016 12:03 pm

( May 19, 2016 - Study to evaluate MM-151 in combination with ONIVYDE plus fluorouracil and leucovorin.

Merck KGaA, Darmstadt, Germany, and Pfizer To Present Avelumab Data In Seven Different Cancers At ASCO Annual Meeting

5/19/2016 12:02 pm

(Pfizer) May 18, 2016 - 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer; two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma; data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers; JAVELIN clinical program rapidly accelerating.

Colombia Battles World's Biggest Drugmaker Over Cancer Drug

5/18/2016 12:04 pm

(ABC News/Associated Press) May 18, 2016 - Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals.

'Right to Try' Bill in Senate for Terminally Ill Patients

5/17/2016 12:00 pm

(Medscape Medical News) May 16, 2016 - A new bill introduced in the Senate is designed to increase access to experimental drugs for dying patients and circumvent the FDA.

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study

5/5/2016 11:04 am

(Yahoo! Finance) May 4, 2016 - RedHill Biopharma Ltd. today announced that the U.S. National Cancer Institute (“NCI”) has awarded the Medical University of South Carolina (“MUSC”) a $1.8 million grant to support a broad range of studies on the feasibility of targeting sphingolipid metabolism for the treatment of a variety of solid tumor cancers.

SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine (galinpepimut-S) Clinical Results at the 13th International Conference of the International Mesothelioma Interest Group (iMig)

5/5/2016 11:01 am

(Morningstar) May 4, 2016 - SELLAS Life Sciences Group today announced that results from a Phase 2 trial of the Company's WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM) were presented at the plenary session of the iMig 2016 Conference, being held May 1-4, 2016, in Birmingham, UK.

New Cancer Drugs Could Treat Lethal Resistant Prostate Cancers

5/2/2016 11:01 am

(Institute of Cancer Research [UK]) May 1, 2016 - Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.

Narrow Band Imaging Can Reduce Recurrence Of Bladder Tumors

5/2/2016 11:01 am

(University of Birmingham [UK]) Apr 28, 2016 - Research into bladder tumour surgery has found that using narrow band imaging can significantly reduce the risk of disease recurrence.

FDA Approval: Cabozantinib (CABOMETYX)

4/26/2016 12:00 pm

( Apr 25, 2016 - On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.

Next Generation ACO Model Letter of Intent Deadline Extended

4/25/2016 11:04 am

(ACCC) Apr 21, 2016 - The Centers for Medicare & Medicaid Services (CMS) announced that the deadline for submission of a Next Generation ACO Model Letter of Intent (LOI) has been extended to May 20, 2016.

Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) With Atezolizumab in the Treatment of Acute Myeloid Leukemia

4/20/2016 12:01 pm

(Astex) Apr 19, 2016 - Astex Pharmaceuticals, Inc. announced today that it has entered into a clinical collaboration with Genentech to evaluate the potential for combining Astex’s next generation hypomethylating agent, guadecitabine (SGI-110), with Genentech’s investigational anti-PD-L1 monoclonal antibody, atezolizumab, in the treatment of acute myeloid leukemia (AML).

OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research (AACR) Annual Meeting 2016

4/20/2016 11:05 am

(Yahoo! Finance) Apr 19, 2016 - OncoSec Medical Incorporated today presented long-term, follow-up data of patients who were treated with its investigational therapy ImmunoPulse™ IL-12 and later went on to receive an anti-PD-1/PD-L1 therapy.